author-photo

M. William Audeh

Cedars-Sinai Medical Center

17

Papers

4560

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Race and response to neoadjuvant chemotherapy according to MammaPrint risk.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pathological complete response in basal subtype tumors to predict improved distant metastasis free survival in the NBRST trial.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Effect of metabolic syndrome on risk of recurrence and immune pathways in invasive lobular carcinoma disparately compared to ductal.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Expression of estrogen receptor variants in ER+ basal-type breast cancers that respond to therapy like ER- breast cancers.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

2016 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (158)
Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology.

2015 Current Treatment Options in Cardiovascular Medicine
Show All
- Source
- Cite
- Save
Citations (11)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1120)
A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)